Cargando…

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma

SIMPLE SUMMARY: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with systemic treatments such as sorafenib. Hepatic arterial infusion chemotherapy (HAIC) is the treatment using an indwelling catheter port system. The regimen of HAIC used in the study is New FP which is co...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Hideki, Niizeki, Takashi, Nagamatsu, Hiroaki, Ueshima, Kazuomi, Nomura, Takako, Kuzuya, Teiji, Kasai, Kazuhiro, Kooka, Yohei, Hiraoka, Atsushi, Sugimoto, Rie, Yonezawa, Takehiro, Ishihara, Akio, Deguchi, Akihiro, Arai, Hirotaka, Shimose, Shigeo, Shirono, Tomotake, Nakano, Masahito, Okamura, Shusuke, Noda, Yu, Kamachi, Naoki, Sakai, Miwa, Suzuki, Hiroyuki, Aino, Hajime, Matsukuma, Norito, Matsugaki, Satoru, Ogata, Kei, Yano, Yoichi, Ueno, Takato, Kajiwara, Masahiko, Itano, Satoshi, Fukuizumi, Kunitaka, Kawano, Hiroshi, Noguchi, Kazunori, Tanaka, Masatoshi, Yamaguchi, Taizo, Kuromatsu, Ryoko, Kawaguchi, Atsushi, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915251/
https://www.ncbi.nlm.nih.gov/pubmed/33562793
http://dx.doi.org/10.3390/cancers13040646
_version_ 1783657194434068480
author Iwamoto, Hideki
Niizeki, Takashi
Nagamatsu, Hiroaki
Ueshima, Kazuomi
Nomura, Takako
Kuzuya, Teiji
Kasai, Kazuhiro
Kooka, Yohei
Hiraoka, Atsushi
Sugimoto, Rie
Yonezawa, Takehiro
Ishihara, Akio
Deguchi, Akihiro
Arai, Hirotaka
Shimose, Shigeo
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Noda, Yu
Kamachi, Naoki
Sakai, Miwa
Suzuki, Hiroyuki
Aino, Hajime
Matsukuma, Norito
Matsugaki, Satoru
Ogata, Kei
Yano, Yoichi
Ueno, Takato
Kajiwara, Masahiko
Itano, Satoshi
Fukuizumi, Kunitaka
Kawano, Hiroshi
Noguchi, Kazunori
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Kawaguchi, Atsushi
Koga, Hironori
Torimura, Takuji
author_facet Iwamoto, Hideki
Niizeki, Takashi
Nagamatsu, Hiroaki
Ueshima, Kazuomi
Nomura, Takako
Kuzuya, Teiji
Kasai, Kazuhiro
Kooka, Yohei
Hiraoka, Atsushi
Sugimoto, Rie
Yonezawa, Takehiro
Ishihara, Akio
Deguchi, Akihiro
Arai, Hirotaka
Shimose, Shigeo
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Noda, Yu
Kamachi, Naoki
Sakai, Miwa
Suzuki, Hiroyuki
Aino, Hajime
Matsukuma, Norito
Matsugaki, Satoru
Ogata, Kei
Yano, Yoichi
Ueno, Takato
Kajiwara, Masahiko
Itano, Satoshi
Fukuizumi, Kunitaka
Kawano, Hiroshi
Noguchi, Kazunori
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Kawaguchi, Atsushi
Koga, Hironori
Torimura, Takuji
author_sort Iwamoto, Hideki
collection PubMed
description SIMPLE SUMMARY: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with systemic treatments such as sorafenib. Hepatic arterial infusion chemotherapy (HAIC) is the treatment using an indwelling catheter port system. The regimen of HAIC used in the study is New FP which is consisted of a fine-powder cisplatin and 5-fluorouracil. In the study, for the patients with locally progressed HCC, such as HCC with vascular invasion, initial administration of local hepatic treatment using HAIC was superior to systemic treatment using sorafenib. ABSTRACT: BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC. METHODS: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy. In total, 1709 consecutive patients with HCC initially treated with New-FP or sorafenib; 1624 (New-FP, n = 644; sorafenib n = 980) were assessed. After propensity score matching (PSM), overall survival (OS) and prognostic factors were assessed (n = 344 each). Additionally, the patients were categorized into four groups: cohort-1 [(without macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort-2 (with MVI), cohort-3 (with EHS), and cohort-4 (with MVI and EHS) to clarify the efficacy of each treatment. RESULTS: New-FP prolonged OS than sorafenib after PSM (New-FP, 12 months; sorafenib, 7.9 months; p < 0.001). Sorafenib treatment, and severe MVI and EHS were poor prognostic factors. In the subgroup analyses, the OS was significantly longer the New-FP group in cohort-2. CONCLUSIONS: Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS.
format Online
Article
Text
id pubmed-7915251
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79152512021-03-01 Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma Iwamoto, Hideki Niizeki, Takashi Nagamatsu, Hiroaki Ueshima, Kazuomi Nomura, Takako Kuzuya, Teiji Kasai, Kazuhiro Kooka, Yohei Hiraoka, Atsushi Sugimoto, Rie Yonezawa, Takehiro Ishihara, Akio Deguchi, Akihiro Arai, Hirotaka Shimose, Shigeo Shirono, Tomotake Nakano, Masahito Okamura, Shusuke Noda, Yu Kamachi, Naoki Sakai, Miwa Suzuki, Hiroyuki Aino, Hajime Matsukuma, Norito Matsugaki, Satoru Ogata, Kei Yano, Yoichi Ueno, Takato Kajiwara, Masahiko Itano, Satoshi Fukuizumi, Kunitaka Kawano, Hiroshi Noguchi, Kazunori Tanaka, Masatoshi Yamaguchi, Taizo Kuromatsu, Ryoko Kawaguchi, Atsushi Koga, Hironori Torimura, Takuji Cancers (Basel) Article SIMPLE SUMMARY: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with systemic treatments such as sorafenib. Hepatic arterial infusion chemotherapy (HAIC) is the treatment using an indwelling catheter port system. The regimen of HAIC used in the study is New FP which is consisted of a fine-powder cisplatin and 5-fluorouracil. In the study, for the patients with locally progressed HCC, such as HCC with vascular invasion, initial administration of local hepatic treatment using HAIC was superior to systemic treatment using sorafenib. ABSTRACT: BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC. METHODS: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy. In total, 1709 consecutive patients with HCC initially treated with New-FP or sorafenib; 1624 (New-FP, n = 644; sorafenib n = 980) were assessed. After propensity score matching (PSM), overall survival (OS) and prognostic factors were assessed (n = 344 each). Additionally, the patients were categorized into four groups: cohort-1 [(without macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort-2 (with MVI), cohort-3 (with EHS), and cohort-4 (with MVI and EHS) to clarify the efficacy of each treatment. RESULTS: New-FP prolonged OS than sorafenib after PSM (New-FP, 12 months; sorafenib, 7.9 months; p < 0.001). Sorafenib treatment, and severe MVI and EHS were poor prognostic factors. In the subgroup analyses, the OS was significantly longer the New-FP group in cohort-2. CONCLUSIONS: Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS. MDPI 2021-02-05 /pmc/articles/PMC7915251/ /pubmed/33562793 http://dx.doi.org/10.3390/cancers13040646 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Iwamoto, Hideki
Niizeki, Takashi
Nagamatsu, Hiroaki
Ueshima, Kazuomi
Nomura, Takako
Kuzuya, Teiji
Kasai, Kazuhiro
Kooka, Yohei
Hiraoka, Atsushi
Sugimoto, Rie
Yonezawa, Takehiro
Ishihara, Akio
Deguchi, Akihiro
Arai, Hirotaka
Shimose, Shigeo
Shirono, Tomotake
Nakano, Masahito
Okamura, Shusuke
Noda, Yu
Kamachi, Naoki
Sakai, Miwa
Suzuki, Hiroyuki
Aino, Hajime
Matsukuma, Norito
Matsugaki, Satoru
Ogata, Kei
Yano, Yoichi
Ueno, Takato
Kajiwara, Masahiko
Itano, Satoshi
Fukuizumi, Kunitaka
Kawano, Hiroshi
Noguchi, Kazunori
Tanaka, Masatoshi
Yamaguchi, Taizo
Kuromatsu, Ryoko
Kawaguchi, Atsushi
Koga, Hironori
Torimura, Takuji
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title_full Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title_fullStr Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title_full_unstemmed Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title_short Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
title_sort survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915251/
https://www.ncbi.nlm.nih.gov/pubmed/33562793
http://dx.doi.org/10.3390/cancers13040646
work_keys_str_mv AT iwamotohideki survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT niizekitakashi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT nagamatsuhiroaki survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT ueshimakazuomi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT nomuratakako survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kuzuyateiji survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kasaikazuhiro survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kookayohei survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT hiraokaatsushi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT sugimotorie survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT yonezawatakehiro survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT ishiharaakio survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT deguchiakihiro survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT araihirotaka survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT shimoseshigeo survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT shironotomotake survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT nakanomasahito survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT okamurashusuke survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT nodayu survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kamachinaoki survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT sakaimiwa survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT suzukihiroyuki survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT ainohajime survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT matsukumanorito survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT matsugakisatoru survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT ogatakei survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT yanoyoichi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT uenotakato survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kajiwaramasahiko survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT itanosatoshi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT fukuizumikunitaka survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kawanohiroshi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT noguchikazunori survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT tanakamasatoshi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT yamaguchitaizo survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kuromatsuryoko survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kawaguchiatsushi survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT kogahironori survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT torimuratakuji survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma
AT survivalbenefitofhepaticarterialinfusionchemotherapyoversorafenibinthetreatmentoflocallyprogressedhepatocellularcarcinoma